CJC-1295 + Ipamorelin 10 mg

CJC-1295 no DAC + Ipamorelin — 10 mg

Purity: ≥98% (HPLC)
Form: lyophilized powder, 3 ml vial
Storage: −20 °C (before opening), +2…+8 °C (after reconstitution, no more than 28 days)
Verification: Janoshik Analytical (Czech Republic) — independent blind test of every batch
Synonyms: Mod GRF (1-29) + Ipamorelin, Modified GRF 1-29 + Ipamorelin
Note: Our product is the no-DAC (Drug Affinity Complex) version

---

Contents

1. What are CJC-1295 + Ipamorelin?
2. Why this combination attracts researchers' attention
3. Two receptors — gas and brake, in simple terms
4. CJC-1295 no DAC (Mod GRF 1-29) — in more detail
5. Ipamorelin — the most selective GHRP
6. Synergy: why they are stronger together
7. With DAC and without DAC — an important distinction
8. Sources

---

1. What are CJC-1295 + Ipamorelin?

This is a combination of two peptides, each of which stimulates the production of one's own growth hormone (GH) — but through different receptors. CJC-1295 no DAC (also known as Mod GRF 1-29) acts through the GHRH receptor. Ipamorelin acts through the ghrelin receptor (GHS-R1a). Together they create synergy: the combined GH response exceeds the sum of the effects of each peptide individually [3].

The fundamental difference from exogenous growth hormone (HGH): these peptides do not introduce ready-made GH from outside. They stimulate the pituitary gland to produce its own growth hormone in a natural pulsatile pattern. The body itself decides how much GH to produce — the peptides merely amplify the signal.

This is precisely why the research literature describes this combination as "physiological" — it mimics the natural mechanism of the nighttime GH peak rather than replacing it with a synthetic hormone.

For research use only. Not a medicinal product. Not intended for use in humans or animals.

---

2. Why this combination attracts researchers' attention

Growth hormone is one of the key regulators of body composition, tissue recovery, and metabolism. With age its secretion declines — by roughly 14% per decade after the age of 30. This phenomenon is called somatopause.

The CJC-1295 + Ipamorelin combination is of interest to researchers for several reasons:

• Two independent receptors. The GHRH receptor (CJC) and the ghrelin receptor (Ipamorelin) are different signaling pathways that converge on the same pituitary cells (somatotrophs). Simultaneous activation of both produces a supra-additive response [3].

• Pulsatile pattern. Unlike exogenous GH, which is administered at a constant dose, this combination stimulates natural GH pulses — closer to the way the body releases growth hormone during deep sleep.

• Selectivity of Ipamorelin. Unlike the early GHRPs (GHRP-6, GHRP-2), Ipamorelin has virtually no effect on cortisol, prolactin, and ACTH [2]. This makes it the "cleanest" GH stimulator among the ghrelin mimetics.

• Preservation of muscle mass during weight loss. In the context of weight reduction, GH stimulation is studied for its ability to support muscle mass while fat tissue is reduced. This is being investigated as a potentially important factor in the "quality" of weight loss — when fat is lost rather than muscle.

All of the effects listed above have been described in preclinical models and early clinical studies of the individual components. No direct randomized studies of the specific CJC-1295 no DAC + Ipamorelin combination have been conducted in humans.

---

3. Two receptors — gas and brake, in simple terms

GH secretion by the pituitary is governed by two signals simultaneously:

GHRH (growth hormone-releasing hormone) — this is the "gas." The hypothalamus releases GHRH, and it tells the pituitary somatotrophs: "Produce and release GH." CJC-1295 mimics this signal.

Somatostatin — this is the "brake." It continuously suppresses GH secretion. For a GH release to occur, one must either increase the gas, or release the brake, or both.

Ghrelin / GHRP — acts through a separate receptor (GHS-R1a) and effectively helps to "release the brake." Ipamorelin mimics this signal.

When the GHRH and the ghrelin signal arrive simultaneously (as happens naturally during deep sleep), a powerful GH peak occurs. The study by Bowers et al. (1999) showed that simultaneous stimulation of both receptors produces a supra-additive response — significantly greater than the sum of the two separate stimuli [3].

---

4. CJC-1295 no DAC (Mod GRF 1-29) — in more detail

CJC-1295 no DAC is a synthetic analog of the first 29 amino acids of endogenous GHRH (it is precisely this fragment that is biologically active). Four amino acid substitutions increase the molecule's resistance to enzymatic breakdown, extending its half-life.

Parameter	Value
Other names	Modified GRF (1-29), Mod GRF 1-29, tetrasubstituted GRF(1-29)
Length	29 amino acids
Type	GHRH analog
Receptor	GHRH-R
Half-life	~30 minutes (no DAC)
Mechanism	Stimulation of GH synthesis and release by pituitary somatotrophs

In the study by Teichman et al. (2006) in healthy volunteers, it was shown that a single injection of CJC-1295 (with DAC) increased plasma GH levels by 2–10-fold over 6 days and IGF-1 by 1.5–3-fold over 9–11 days [1]. The no-DAC version (our product) acts for a shorter time but provides a more physiological pulsatile profile of GH secretion.

---

5. Ipamorelin — the most selective GHRP

Ipamorelin is a third-generation pentapeptide of the GHRP (Growth Hormone Releasing Peptides) class. It was described by Raun et al. in 1998 as the first "selective" GH secretagogue [2].

Parameter	Value
Length	5 amino acids
Type	GHRP (ghrelin mimetic)
Receptor	GHS-R1a (ghrelin receptor)
Key property	Selectivity — stimulates GH without significant effect on cortisol, prolactin, and ACTH

What makes Ipamorelin special:

GHRP-6 (first generation) — strongly stimulates GH, but at the same time raises cortisol and prolactin and causes sharp hunger through activation of the ghrelin system.

GHRP-2 (second generation) — stronger in terms of GH, but still raises cortisol and prolactin.

Ipamorelin (third generation) — a comparable GH response, but minimal effect on cortisol and prolactin [2]. It is precisely this selectivity profile that explains why Ipamorelin became the preferred GHRP in research protocols.

---

6. Synergy: why they are stronger together

The key study: Bowers et al. (1999) showed that simultaneous administration of GHRH and GHRP to healthy volunteers elicits a GH response significantly exceeding the sum of the responses to each peptide individually [3]. This effect is called supra-additive.

The mechanism is explained by the fact that GHRH and the ghrelin mimetics act through two independent intracellular cascades in the same cells:

• CJC-1295 (GHRH pathway): activates a cAMP-dependent cascade → GH synthesis and secretion
• Ipamorelin (ghrelin pathway): activates a calcium-dependent cascade → amplification of the GH pulse

When both cascades are active simultaneously, the cell receives two convergent signals to release GH — and the response sums up nonlinearly.

An analogy from the research literature: if GHRH is the "gas," and a drop in somatostatin is "releasing the brake," then ghrelin/GHRP is the "nitro." All three processes occur simultaneously during the nighttime GH peak, and the CJC + Ipamorelin combination reproduces two of the three.

---

7. With DAC and without DAC — an important distinction

There are two variants of CJC-1295, and they are often confused:

Parameter	CJC-1295 with DAC	CJC-1295 without DAC (Mod GRF 1-29)
DAC (Drug Affinity Complex)	Present — binds to albumin	Absent
Half-life	~6–8 days	~30 minutes
GH secretion profile	Sustained elevation of the average level	Discrete pulses (closer to physiology)
Administration	1–2 times per week	Daily (usually before sleep)

Our product is the no-DAC version. This is a deliberate choice: a shorter duration of action provides pulsatile GH secretion, which is closer to the natural circadian rhythm. Sustained elevation of GH (as with the DAC version) is associated in the literature with more pronounced insulin resistance and receptor desensitization.

---

Sources

1. Teichman S.L. et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J. Clin. Endocrinol. Metab., 91(3): 799–805, 2006. PubMed

2. Raun K. et al. Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol., 139(5): 552–561, 1998. PubMed

3. Bowers C.Y. et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114: 1537–1545, 1984. Synergy data: Jaffe C.A. et al. Enhancement of the growth hormone response to GHRH by GHRP-6. J. Clin. Endocrinol. Metab., 78: 1359–1364, 1999.

4. Ionescu M., Frohman L.A. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J. Clin. Endocrinol. Metab., 91(12): 4792–4797, 2006. PubMed

5. Bowers C.Y. et al. Sustained elevation of pulsatile growth hormone secretion in women during continuous GHRP-2 infusion. J. Clin. Endocrinol. Metab., 89(5): 2478–2487, 2004. PubMed

---

This material was prepared by the LONGIVIYA editorial team on the basis of published scientific research. The information is intended solely for educational purposes and does not constitute a medical recommendation.

For research use only. Not a medicinal product. Not intended for use in humans or animals. Independent verification of every batch: Janoshik Analytical (Czech Republic).